Theravance Biopharma
TBPH
TBPH
93 hedge funds and large institutions have $1.55B invested in Theravance Biopharma in 2018 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 21 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
8% more funds holding
Funds holding: 86 → 93 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.16% less ownership
Funds ownership: 87.19% → 86.03% (-1.2%)
Holders
93
Holding in Top 10
1
Calls
$1.69M
Puts
$983K
Top Buyers
| 1 | +$23.9M | |
| 2 | +$15.7M | |
| 3 | +$8.32M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.12M |
| 5 |
Millennium Management
New York
|
+$2.89M |
Top Sellers
| 1 | -$26.8M | |
| 2 | -$14M | |
| 3 | -$6.53M | |
| 4 |
BNP Paribas Asset Management
Paris,
France
|
-$5.4M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.72M |